We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Podcast on Emerging Treatment Options for Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumors.
- Authors
Lowe, Eric; Mossé, Yael P.
- Abstract
Anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT) are rare cancers observed predominantly in children and young adults. ALCL accounts for 10–15% of all pediatric non-Hodgkin lymphomas and is commonly diagnosed at an advanced stage of disease. In children, 84–91% of cases of ALCL harbor an anaplastic lymphoma kinase (ALK) gene translocation. IMT is a rare mesenchymal neoplasm that also tends to occur in children and adolescents. Approximately 50–70% of IMT cases involve rearrangements in the ALK gene. A combination of chemotherapeutic drugs is typically used for children with ALK-positive ALCL, and the only known curative therapy for ALK-positive IMT is complete surgical resection. Crizotinib, a first-generation ALK inhibitor, was approved in the USA in 2021 for pediatric patients and young adults with relapsed or refractory ALK-positive ALCL; however, its safety and efficacy have not been established in older adults. In 2022, crizotinib was approved for adult and pediatric patients with unresectable, recurrent, or refractory ALK-positive IMT. This podcast provides an overview of ALK-positive ALCL and IMT. We discuss the current treatment landscape, the role of ALK tyrosine kinase inhibitors, and areas of future research.
- Subjects
CANCER; NON-Hodgkin's lymphoma; PATIENT safety; CANCER relapse; ANAPLASTIC large-cell lymphoma; RARE diseases; ANTINEOPLASTIC agents; MESENCHYMAL stem cells; MUSCLE cells; CANCER patients; PEDIATRICS; CANCER chemotherapy; ANAPLASTIC lymphoma kinase; STREAMING media; DRUG efficacy; ONCOLOGISTS; PROGRESSION-free survival
- Publication
Oncology & Therapy, 2024, Vol 12, Issue 2, p247
- ISSN
2366-1070
- Publication type
Article
- DOI
10.1007/s40487-024-00275-6